GlassScriptPhysician profile
Marvin Feldman
NPI 1336254424
$47,352.67
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2020: $9,212 · 2021: $6,718.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $39,344.13 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,823.12 | 2019 | |
| Glaxosmithkline, LLC. | $1,938.62 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $445.98 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $368.73 | 2019 | |
| Exelixis INC. | $271.00 | 2019 | |
| Genzyme Corporation | $253.97 | 2019 | |
| Daiichi Sankyo INC. | $209.57 | 2019-2020 | |
| Incyte Corporation | $140.41 | 2019 | |
| Eisai INC. | $105.64 | 2019 | |
| Genentech USA, INC. | $77.69 | 2019 | |
| Sanofi-Aventis U.S. LLC | $59.99 | 2019 | |
| Janssen Biotech, INC. | $41.90 | 2019 | |
| Pfizer INC. | $40.41 | 2019 | |
| Gilead Sciences, INC. | $32.69 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $31.37 | 2019 | |
| Seagen INC. | $30.78 | 2019 | |
| Amgen INC. | $24.71 | 2019 | |
| Emd Serono, INC. | $19.30 | 2019 | |
| Astellas Pharma US INC | $19.27 | 2019 | |
| Dendreon Pharmaceuticals LLC | $18.18 | 2020 | |
| Alexion Pharmaceuticals, INC. | $14.36 | 2019 | |
| Array Biopharma INC | $13.95 | 2019 | |
| Puma Biotechnology, INC. | $12.52 | 2019 | |
| Abbvie INC. | $11.50 | 2019 | |
| Clovis Oncology, INC. | $2.88 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marvin Feldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.